All In Biotech

NDA 020819 · Abbvie

Zemplar

Paricalcitol · Intravenous · Vitamin D2 Analog; Vitamin D Analog

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Oct 20, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Apr 17, 1998

Approved uses

3

Original approval plus efficacy supplements

Registered trials

101

23 Phase 3, 1 recruiting

FAERS reports

14,054

12,725 serious, 8,430 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 1, 2024.

ZEMPLAR is indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease (CKD) on dialysis. ZEMPLAR is a vitamin D analog indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease on dialysis ( 1 ).

Mechanism: Paricalcitol is a synthetic, biologically active vitamin D 2 analog. Preclinical and in vitro studies have demonstrated that paricalcitol's biological actions are mediated through binding of the vitamin D receptor (VDR), which results in the selective activation of vitamin D responsive pathways. Vitamin D and paricalcitol have been shown to reduce PTH levels by inhibiting PTH synthesis and secretion.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • ZEMPLAR · PARICALCITOL 0.01MG/2ML (0.005MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • ZEMPLAR · PARICALCITOL 0.005MG/ML (0.005MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • ZEMPLAR · PARICALCITOL 0.002MG/ML (0.002MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Paricalcitol" as an intervention, any sponsor and status, largest first.

All 101 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death3,570
  • cardiac disorder622
  • myocardial infarction584
  • sepsis483
  • cardio-respiratory arrest477
  • dyspnoea395
  • cardiac failure348
  • renal failure308
  • pneumonia303
  • nausea302
  • cerebrovascular accident285
  • asthenia277

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200428
200571
2006148
2007159
2008335
2009705
2010449
2011499
2012368
20131,819
20142,367
20152,117
20161,826
2017797
2018628
2019515
2020377
2021268
2022246
2023212
202460
202531
202629

Recalls

1 FDA enforcement reports for this application.

  • May 14, 2012 · Class II · Terminated

    CGMP Deviations: There is potential that Abbott's third party manufacturer, Hospira, may have applied a foreign (incorrect) stopper to vials in a specific lot of Zemplar Injection.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zemplar* (Paricalcitol)

2024 spending

$20K

Beneficiaries

11

32 claims

Per beneficiary

$1,831

$12.90 per unit

View as table
YearSpending
2020$38,403
2021$18,413
2022$23,926
2023$19,438
2024$20,136

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 147 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.